Immunogenicity and protection conferred by a recombinant Mycobacterium marinum vaccine against Buruli ulcer

Bryan E. Hart, Laura P. Hale, Sunhee Lee

Research output: Contribution to journalArticle

4 Scopus citations


Mycobacterium ulcerans (MU) infection causes the disfiguring necrotic skin disease, Buruli ulcer (BU). While vaccination with Mycobacterium bovis BCG provides nominal antigenic cross-reactivity for induction of immunity against experimental MU infection, a mycobacterial species with greater genetic homology to Mycobacterium ulcerans may serve as a richer source of cross-protective immunogens and lack the pathological features of MU-based vaccines. Mycobacterium marinum, a highly homologous genetic relative of MU, could be used to satisfy these criteria and, as such, we have generated a recombinant M. marinum strain expressing the immunodominant, protective MU-Ag85A. The immunogenicity and protection achieved by murine vaccination with this strain are superior to standard BCG vaccination and may serve as a foundation for developing more effective BU vaccines.

Original languageEnglish (US)
Pages (from-to)88-91
Number of pages4
JournalTrials in Vaccinology
StatePublished - Jan 1 2016
Externally publishedYes



  • Ag85A
  • Buruli ulcer
  • M. marinum
  • Mycobacterium ulcerans
  • Vaccine

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this